Results 71 to 80 of about 250 (109)

0589 Dose Titration of Once-Nightly Sodium Oxybate: Analysis of Interim Data From RESTORE

SLEEP, 2023
Abstract Introduction FT218 (LUMRYZ™) is an investigational once-nightly sodium oxybate (ON-SXB) for treatment of adults with narcolepsy type 1 (NT1) or type 2 (NT2). The efficacy and safety of ON-SXB at doses 6, 7.5, and 9 g in patients with NT1/NT2 were confirmed in the phase 3 REST-ON clinical ...
Asim Roy, Brian Abaluck, Thomas Stern, Clete Kushida, Jordan Dubow, Jennifer Gudeman   +5 more
openaire   +1 more source

Pharmacokinetics and Dose Proportionality of FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy (501)

Neurology, 2020
Jordan Dubow, David Seiden
exaly   +2 more sources

Pharmacokinetics and Formulation Selection of FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy (495)

Neurology, 2020
Jordan Dubow, David Seiden
exaly   +2 more sources

0573 Application of AASM Clinical Significance Thresholds to Once-Nightly Sodium Oxybate for Improvement in Narcolepsy Symptoms

SLEEP, 2023
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release treatment, was evaluated for the treatment of narcolepsy in adults in the phase 3 REST-ON clinical trial (NCT02720744).
Thomas Roth, Michael Thorpy, Clete Kushida, Anne Morse, Jordan Dubow, Jennifer Gudeman, Yves Dauvilliers   +6 more
openaire   +1 more source

Understanding the Patient Experience with Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment [PDF]

Brain Sciences
Maria Picone, Christopher Defelice, Anne Marie Morse   +2 more
exaly   +2 more sources

0638 Stability of Once-Nightly Sodium Oxybate in Alternative Liquid Reconstitution Vehicles

SLEEP
Abstract Introduction LUMRYZ™ is a once-nightly formulation of sodium oxybate (ON-SXB) containing both immediate and pH-dependent controlled-release granules designed to be reconstituted in water and administered orally.
Maggie Lavender, Ellen Wermter, Anne Morse, Matthew Horsnell, Jason Vaughn, Frederik Ascencion, Jennifer Gudeman   +6 more
openaire   +1 more source

0636 Assessing Usability of Once-Nightly Sodium Oxybate Extended-Release Oral Suspension for Narcolepsy

SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender, Ellen Wermter, Luis Ortiz, Anne Morse, Matthew Horsnell, Jennifer Gudeman   +5 more
openaire   +1 more source

0836 Consistent Efficacy of Once-Nightly Sodium Oxybate on Disrupted Nighttime Sleep in People with Narcolepsy

SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers, Michael Thorpy, Thomas Roth, Clete Kushida, Anne Morse, John Harsh, Luis Ortiz, Jennifer Gudeman   +7 more
openaire   +1 more source

DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE

Chest, 2022
ASIM ROY, BRIAN ABALUCK, THOMAS P STERN, CLETE KUSHIDA, DAVID SEIDEN, JENNIFER GUDEMAN   +5 more
openaire   +1 more source

Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE

Sleep Medicine, 2022
T. Stern, A. Roy, C. Shapiro, J. Harsh, A. Ajayi, S. Ibrahim, D. Seiden, J. Dubow, J. Gudeman   +8 more
openaire   +1 more source